NervGen Pharma Corp.
TSXV NGEN.V
NervGen Pharma Corp. Free Cash Flow for the year ending December 31, 2023: USD -8.63 M
-
NervGen Pharma Corp. Free Cash Flow for the year ending December 31, 2022 was USD -13.13 M, a -99.82% change year over year.
-
NervGen Pharma Corp. Free Cash Flow for the year ending December 31, 2021 was USD -6.57 M, a -32.73% change year over year.
-
NervGen Pharma Corp. Free Cash Flow for the year ending December 31, 2020 was USD -4.95 M, a 20.48% change year over year.
-
NervGen Pharma Corp. Free Cash Flow for the year ending December 31, 2019 was USD -6.23 M, a -628.28% change year over year.
| Date | Free Cash Flow | Operating Cash Flow | Net Cash Used For Investing Activities | Net Cash Used Provided By Financing Activities |
|---|
| CEO | Mr. Michael Kelly |
| IPO Date | March 15, 2019 |
| Location | Canada |
| Headquarters | 2955 Virtual Way |
| Employees | 11 |
| Sector | Health Care |
| Industries | |
NervGen Pharma Corp., together with its subsidiaries, engages in the discovery, development, and commercialization of pharmaceutical treatments for medical conditions related to nervous system damage. Its lead product candidate is NVG-291 that is in phase 1 clinical trial for the treatment of spinal cord injuries (SCI), multiple sclerosis, and Alzheimer's disease. The company has a licensing agreement with Case Western Reserve University to research, develop, and commercialize a patented technology with therapeutic potential for SCI and other conditions associated with nerve damage. NervGen Pharma Corp. was incorporated in 2017 and is based in Vancouver, Canada.
Past 5 years
USD 0.91
StockViz Staff
January 15, 2025
Any question? Send us an email